Brad Best Comics

At the Heart of Science



CORNOVUS Pharmaceuticals, Inc. is a cutting edge pharmaceutical company focused on bringing new treatment for late stage heart failure to market.

more >


Our Technology

The lead technology from CORNOVUS is a compound currently referred to as MRS2339

MRS2339 takes a novel approach to heart failure treatment, targeting P2X4 receptors

It is believed that MRS2339 works by increasing myocardial cyclic guanosine-monophosphate (GMP), which may play a role in cardia function and reperfusion

This unique mechanism may be complementary to other approaches

  • MRS2339 has shown promising results in animal testing

  • Administration by sc or iv infusion ensures compliance

  • This treatment has the potential to provide a valuable new option to more than 300,000 patients suffering from moderate to severe heart failure in the US alone